Amgen, the maker of evolocumab (Repatha) funded the research, paid EVERY author on the paper, led by Harvard researchers, and the findings were published in the prestigious New England Journal of Medicine May 4, 2017. If you take the drug, evolocumab (Repatha), your LDL will go down but you won’t live any longer. IT’S ALL ABOUT INFLAMMATION AND OXIDATION.
In the 1960s, the Sugar industry initiated, examined the drafts of papers, and paid $6500 (equivalent of $48,000 in 2016 dollars) to Harvard professors, Drs Fredrick Stare and Mark Hegsted, both dead now, to protect sugar even though sugar was found to be a major cause of heart disease.
“research” that was bought from a famous institution, Harvard, published in a famous medical journal, New England Journal of Medicine, was not questioned and negatively influenced the medical profession and public for decades, costing incalculable number of lives and dollars.
